Trial · NCT01502813
Citicoline, Creatine, and Omega-3 Effects in Middle Age Women
NCT01502813, Not applicable, Completed, Deborah Yurgelun-Todd; results first posted 2021-04-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Citicoline, Creatine, and Omega-3 Effects in Middle Age Women. Trials, record NCT01502813. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01502813
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Citicoline, Creatine, and Omega-3 Effects in Middle Age Women
- NCT number
- NCT01502813
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 40 participants, actual
- Lead sponsor
- Deborah Yurgelun-Todd
- Conditions
- Cognitive Benefits
- Interventions
- Citicoline, Omega-3 Fatty Acids and Creatine
- First posted
- 2012-01-02
- Last updated
- 2021-04-22
- Results first posted
- 2021-04-22
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in California Verbal Learning Test (CVLT) That Measure Attention and Memory at 14 Days | Baseline and 14 days from baseline | List B in the California Verbal Learning Test (CVLT) score range 1-16; the score is the number of words recalled so higher scores = better performance/more words recalled. |
| Primary | Change From Baseline in WAIS-IV Block Design Subtest A That Measures Attention and Memory at 28 Days | Baseline and 28 days from baseline | WAIS-IV Block Design Subtest A test of visuoconstructional ability is recognized as a test of visuospatial planning and function. It has been shown to be correlated with measures of general intellectual ability. The score range for this measure is 0-129. A score of 90-110 is average for a standard score. The higher the score the better the outcome. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in California Verbal Learning Test (CVLT) That Measure Attention and Memory at 14 Days | Baseline and 14 days from baseline | score on a scale | MEDIAN | |
| PRIMARY | Change From Baseline in WAIS-IV Block Design Subtest A That Measures Attention and Memory at 28 Days | Baseline and 28 days from baseline | Score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in California Verbal Learning Test (CVLT) That Measure Attention and Memory at 14 Days | Citicoline, Creatine, and Omega-3 Arm | 10 | Full Range 1 to 16 | score on a scale | |
| Change From Baseline in WAIS-IV Block Design Subtest A That Measures Attention and Memory at 28 Days | Citicoline, Creatine, and Omega-3 Arm | 98 | Full Range 0 to 130 | Score on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Citicoline, Creatine, and Omega-3 Arm | 40 | |
| Overall Study | COMPLETED | Citicoline, Creatine, and Omega-3 Arm | 40 | |
| Overall Study | NOT COMPLETED | Citicoline, Creatine, and Omega-3 Arm | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Citicoline, Creatine, and Omega-3 Arm | 0 | 40 |
| Total, other adverse events | Citicoline, Creatine, and Omega-3 Arm | 0 | 40 |
| Total, serious adverse events | Citicoline, Creatine, and Omega-3 Arm | 0 | 40 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Block Copy Test | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01502813
GET https://conductscience.org/api/trials/v1/NCT01502813/registered